Acceleron and Celgene Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Acceleron Pharma, Inc. has announced it has received the upfront payment from Celgene Corporation following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the collaboration between the two companies previously announced on February 20, 2008.
The collaboration between Acceleron and Celgene is a joint development, joint commercialization agreement on ACE-011, a first-in-class, novel bone-forming compound, and three discovery stage programs for the treatment of cancer and cancer-related bone loss.
